Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function

Prior treatment

• Patients with large fluctuations or rapid deterioration of renal function within 2 weeks before administration, as judged by the investigator;
• Subjects receiving renal replacement therapy within 3 months of the screening period or during the expected trial period;
• Within 3 months before screening, patients with underlying diseases that induced chronic kidney disease and were poorly controlled according to the investigator's evaluation.

Other illness

• Suspected allergy to the study drug or any component of the study drug;
• Patients with cardiogenic shock, severe conduction block, sick sinus syndrome, heart failure, sustained tachyarrhythmia, torsades de pointes (Tdp) or ventricular tachycardia, history of clinically significant T wave changes, myocardial infarction, angina pectoris;
• People with conditions associated with reduced neuromuscular transmission (myasthenia gravis, Lambert-Eaton syndrome, Duchenne muscular dystrophy);
• Patients with a history of gastric or intestinal surgery that may affect drug absorption;
• Participants with renal insufficiency who were judged by the investigator to be ineligible for the study;

• Sign the informed consent before the trial, and fully understand the content, process and possible adverse reactions of the trial;
• Male or female subjects aged 18 to 65 (including 18 and 65);
• Body mass index (BMI) ranges from 19 kg/m2 to 28 kg/m2 (including 18 and 28);
• The glomerular filtration rate should meet the following criteria (GFR, mL/min): Subjects with mild renal impairment: 60-89 mL/min; Subjects with moderate renal impairment: 30-59 mL/min.